Beverley Hunt

Last updated

Beverley Jane Hunt is professor of thrombosis and haemostasis at King's College, London, [1] consultant in the departments of haematology, rheumatology [2] and pathology [3] and director of the Haemostasis Research Unit at Guy's and St Thomas' Foundation Trust, medical director of Thrombosis UK and previous president of Walthamstow Hall Old Girls Association. [4] She was educated at Walthamstow Hall [5] and University of Liverpool.

Contents

Specialist interest and research

Hunt is author and co-author of many peer-reviewed research articles. She has a specialist clinical and research interest in venous thromboembolism, thromboprophylaxis, antiphospholipid syndrome, lupus erythematosus, and obstetric haematology. [6] Prof. Hunt has served as the Steering Committee Chair of the World Thrombosis Day Steering Committee since 2019. She has been a member of the steering committee since the campaign's inception in 2014. [7]

Books

She is co-editor of The Obstetric Hematology Manual, [8] and also of An Introduction to Vascular Biology: From Basic Science to Clinical Practice. [9]

Society memberships

She is the founder and co-lead of the British Society for Haematology Obstetric Haematology Group [10] from 2004, a founder member of the society's Education Committee from 2009, [11] and a member of the British Society for Haemostasis and Thrombosis, [12] the International Society of Thrombosis and Haemostasis [13] and is a Fellow of the Royal College of Physicians. She has been a member of the World Thrombosis Day steering committee since the campaigns' inception in 2014. [14]

Contribution to national guidelines

She was the co-author of several reports and guidelines: the British Society of Haematology's "Guidelines for TTP" in 2001 and 2002, and an advisor on the Royal College of Obstetricians and Gynaecologists: "Advice on preventing deep vein thrombosis for pregnant women travelling by air" [15] produced in October 2001 and an advisor on the Royal College of Obstetricians guideline on: "Thromboprophylaxis in pregnancy" [16] in 2004 and 2009.

She is a member of "The Independent Expert Panel on Venous Thromboembolism" 2005/6, and co-author on the "International Consensus report on the investigation and management of primary immune thrombocytopenia", [17] the "Clinical guidelines for testing for heritable thrombophilia" [18] co-author on the "Guideline for investigation and management of adults and children presenting with a thrombocytosis" [19] the "Management of bleeding following major trauma: an updated European guideline". [20]

She was a member of the National Institute for Health and Care Excellence (NICE) guidelines development group for: "reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital" [21] published in 2010 and also the "Acute management of venous thromboembolism" published in 2012. On behalf of Thrombosis UK, she was also a member of the committee producing the NICE Quality standards on VTE prevention. [22]

Charity

Hunt is co-founder and medical director of Thrombosis UK [23] which campaigns to raise awareness of thrombosis—in particular the risk of hospital-acquired deep vein thrombosis by mandating risk assessment. Prof. Hunt was a founding member of the World Thrombosis Day [24] steering committee, which is the global awareness campaign of the International Society on Thrombosis and Haemostasis (ISTH) that is recognized on October 13 each year and raises awareness of thrombosis.

Honours and awards

She was winner in the Diagnostic/Laboratory category winner at the NHS London Innovation awards 2009 for “Detection of antiphospholipid antibodies based in heparin resistance.”, [25] and won the 2011 Research paper of the year at the Briths Medical Journal Group for a paper titled "Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial" [26] [27] [28] which was published in The Lancet (2010;376:23–32).

Hunt was appointed Officer of the Order of the British Empire (OBE) in the 2019 Birthday Honours for services to medicine. [29]

Related Research Articles

<span class="mw-page-title-main">Anticoagulant</span> Class of drugs

An anticoagulant, commonly known as a blood thinner, is a chemical substance that prevents or reduces the coagulation of blood, prolonging the clotting time. Some occur naturally in blood-eating animals, such as leeches and mosquitoes, which help keep the bite area unclotted long enough for the animal to obtain blood.

<span class="mw-page-title-main">Thrombosis</span> Formation of blood clots inside the blood vessels

Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. When a blood vessel is injured, the body uses platelets (thrombocytes) and fibrin to form a blood clot to prevent blood loss. Even when a blood vessel is not injured, blood clots may form in the body under certain conditions. A clot, or a piece of the clot, that breaks free and begins to travel around the body is known as an embolus.

<span class="mw-page-title-main">Pulmonary embolism</span> Blockage of an artery in the lungs

Pulmonary embolism (PE) is a blockage of an artery in the lungs by a substance that has moved from elsewhere in the body through the bloodstream (embolism). Symptoms of a PE may include shortness of breath, chest pain particularly upon breathing in, and coughing up blood. Symptoms of a blood clot in the leg may also be present, such as a red, warm, swollen, and painful leg. Signs of a PE include low blood oxygen levels, rapid breathing, rapid heart rate, and sometimes a mild fever. Severe cases can lead to passing out, abnormally low blood pressure, obstructive shock, and sudden death.

<span class="mw-page-title-main">Venous thrombosis</span> Blood clot (thrombus) that forms within a vein

Venous thrombosis is the blockage of a vein caused by a thrombus. A common form of venous thrombosis is deep vein thrombosis (DVT), when a blood clot forms in the deep veins. If a thrombus breaks off (embolizes) and flows to the lungs to lodge there, it becomes a pulmonary embolism (PE), a blood clot in the lungs. The conditions of DVT only, DVT with PE, and PE only, are all captured by the term venous thromboembolism (VTE).

<span class="mw-page-title-main">Deep vein thrombosis</span> Formation of a blood clot (thrombus) in a deep vein

Deep vein thrombosis (DVT) is a type of venous thrombosis involving the formation of a blood clot in a deep vein, most commonly in the legs or pelvis. A minority of DVTs occur in the arms. Symptoms can include pain, swelling, redness, and enlarged veins in the affected area, but some DVTs have no symptoms.

D-dimer is a dimer that is a fibrin degradation product, a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. It is so named because it contains two D fragments of the fibrin protein joined by a cross-link, hence forming a protein dimer.

<span class="mw-page-title-main">Thrombophilia</span> Abnormality of blood coagulation increasing the risk of blood clotting (thrombosis)

Thrombophilia is an abnormality of blood coagulation that increases the risk of thrombosis. Such abnormalities can be identified in 50% of people who have an episode of thrombosis that was not provoked by other causes. A significant proportion of the population has a detectable thrombophilic abnormality, but most of these develop thrombosis only in the presence of an additional risk factor.

<span class="mw-page-title-main">Paget–Schroetter disease</span> Formation of blood clots in the deep veins of the arms

Paget–Schroetter disease is a form of upper extremity deep vein thrombosis (DVT), a medical condition in which blood clots form in the deep veins of the arms. These DVTs typically occur in the axillary and/or subclavian veins.

<span class="mw-page-title-main">Vascular disease</span> Medical condition

Vascular disease is a class of diseases of the vessels of the circulatory system in the body, including blood vessels – the arteries and veins, and the lymphatic vessels. Vascular disease is a subgroup of cardiovascular disease. Disorders in this vast network of blood and lymph vessels can cause a range of health problems that can sometimes become severe, and fatal. Coronary heart disease for example, is the leading cause of death for men and women in the United States.

<span class="mw-page-title-main">Post-thrombotic syndrome</span> Residual symptoms following thrombosis (clots in the blood vessels)

Post-thrombotic syndrome (PTS), also called postphlebitic syndrome and venous stress disorder is a medical condition that may occur as a long-term complication of deep vein thrombosis (DVT).

<span class="mw-page-title-main">Cerebral venous sinus thrombosis</span> Presence of a blood clot in the dural venous sinuses or cerebral veins

Cerebral venous sinus thrombosis (CVST), cerebral venous and sinus thrombosis or cerebral venous thrombosis (CVT), is the presence of a blood clot in the dural venous sinuses, the cerebral veins, or both. Symptoms may include severe headache, visual symptoms, any of the symptoms of stroke such as weakness of the face and limbs on one side of the body, and seizures, which occur in around 40% of patients.

Helge Stormorken was a Norwegian veterinarian and physician.

<span class="mw-page-title-main">Betrixaban</span> Chemical compound

Betrixaban is an oral anticoagulant drug which acts as a direct factor Xa inhibitor. Betrixaban is FDA approved for venous thrombosis prevention in adults hospitalized for an acute illness who are at risk for thromboembolic complications. Compared to other directly acting oral anticoagulants betrixaban has relatively low renal excretion and is not metabolized by CYP3A4.

Prothrombin G20210A is a genotypic trait that provides a prompter coagulation response. It increases the risk of blood clots including from deep vein thrombosis, and of pulmonary embolism. One copy of the mutation increases the risk of a blood clot from 1 in 1,000 per year to 2.5 in 1,000. Two copies increases the risk to up to 20 in 1,000 per year. Most people never develop a blood clot in their lifetimes.

Thrombosis UK is a UK based charity whose stated mission is to increase awareness of thrombosis among the public and health professionals, and to raise research funds to improve patient care through improved prevention and treatment of venous thromboembolic disease.

Brian Trevor Colvin is a British haematologist.

<span class="mw-page-title-main">Thrombosis prevention</span> Medical treatment to prevent clotting within blood vessels

Thrombosis prevention or thromboprophylaxis is medical treatment to prevent the development of thrombosis in those considered at risk for developing thrombosis. Some people are at a higher risk for the formation of blood clots than others, such as those with cancer undergoing a surgical procedure. Prevention measures or interventions are usually begun after surgery as the associated immobility will increase a person's risk.

Henri Bounameaux is a known clinical faculty and Professor of Medicine (hon), specialized in internal and vascular medicine (angiology), and general medicine.

<span class="mw-page-title-main">Embolic and thrombotic events after COVID-19 vaccination</span> Post vaccination adverse effects

Post-vaccination embolic and thrombotic events, termed vaccine-induced immune thrombotic thrombocytopenia (VITT), vaccine-induced prothrombotic immune thrombocytopenia (VIPIT), thrombosis with thrombocytopenia syndrome (TTS), vaccine-induced immune thrombocytopenia and thrombosis (VITT), or vaccine-associated thrombotic thrombocytopenia (VATT), are rare types of blood clotting syndromes that were initially observed in a number of people who had previously received the Oxford–AstraZeneca COVID‑19 vaccine (AZD1222) during the COVID‑19 pandemic. It was subsequently also described in the Janssen COVID‑19 vaccine, leading to the suspension of its use until its safety had been reassessed. On 5 May 2022 the FDA posted a bulletin limiting the use of the Janssen Vaccine to very specific cases due to further reassessment of the risks of TTS, although the FDA also stated in the same bulletin that the benefits of the vaccine outweigh the risks.

<span class="mw-page-title-main">Claire McLintock</span> Haematologist and obstetric physician (1965–2022)

Marie Claire McLintock was a New Zealand haematologist and obstetric physician. She was an expert in medical conditions and disorders related to bleeding and blood clotting, and medical problems associated with pregnancy.

References

  1. ↑ "Comment" (PDF). King's College London. February 2009. Archived (PDF) from the original on 2014-01-07. Retrieved 2014-01-15.
  2. ↑ "The Louise Coote Lupus Unit team". Guysandstthomas.nhs.uk. Archived from the original on 2012-09-02. Retrieved 2012-07-18.
  3. ↑ "Blood Sciences contact details". GSTS. Archived from the original on 2013-02-10. Retrieved 2012-07-18.
  4. ↑ "Professor Hunt wins 'Medical Oscar'". Walthamstow-hall.co.uk. 2011-05-26. Archived from the original on 2014-01-07. Retrieved 2012-07-18.
  5. ↑ "Alumnae Profiles". Walthamstow-hall.co.uk. 2011-05-29. Archived from the original on 2011-04-24. Retrieved 2012-07-18.
  6. ↑ "Obstetric haematology information for patients". Guysandstthomas.nhs.uk. Archived from the original on 2012-09-02. Retrieved 2012-07-18.
  7. ↑ Hunt, Beverley. "Steering Committee Char". World Thrombosis Day website. Archived from the original on 2022-10-20. Retrieved 2022-10-20.
  8. ↑ "The Obstetric Hematology Manual – Academic and Professional Books – Cambridge University Press". Cambridge.org. Retrieved 2012-07-18.
  9. ↑ Hunt, Beverley J.; Poston, Lucilla; Schachter, Michael (2002-07-25). An Introduction to Vascular Biology: From Basic Science to Clinical Practice – Beverley J. Hunt, Lucilla Poston – Google Books. Cambridge University Press. ISBN   9780521796521. Archived from the original on 2024-07-26. Retrieved 2012-07-18.
  10. ↑ "British Society for Haematology ABOUT US". B-s-h.org.uk. Retrieved 2014-01-16.
  11. ↑ "British Society for Haematology New BSH education committee". Archived from the original on 2012-01-06. Retrieved 2012-05-30.
  12. ↑ "British Society for Haemostasis and Thrombosis Homepage". BSHT. 16 December 2013. Archived from the original on 2013-10-09. Retrieved 2014-01-15.
  13. ↑ "International Society on Thrombosis & Haemostasis". Archived from the original on June 5, 2012. Retrieved May 30, 2012.
  14. ↑ Hunt, Beverley. "World Thrombosis Day website". Archived from the original on 2022-10-20. Retrieved 2022-10-20.
  15. ↑ http://www.rcog.org.uk/womens-health/clinical.../air-travel-and-pregnancy . Retrieved May 30, 2012.{{cite web}}: Missing or empty |title= (help)[ dead link ]
  16. ↑ "Wiley: Journals, books, and online products and services" (PDF). Blackwellpublishing.com. Retrieved 2014-01-16.[ permanent dead link ]
  17. ↑ Provan, Drew; Stasi, Roberto; Newland, Adrian C.; Blanchette, Victor S.; Bolton-Maggs, Paula; Bussel, James B.; Chong, Beng H.; Cines, Douglas B.; Gernsheimer, Terry B.; Godeau, Bertrand; Grainger, John; Greer, Ian; Hunt, Beverley J.; Imbach, Paul A.; Lyons, Gordon; McMillan, Robert; Rodeghiero, Francesco; Sanz, Miguel A.; Tarantino, Michael; Watson, Shirley; Young, Joan; Kuter, David J. (2010). "International consensus report on the investigation and management of primary immune thrombocytopenia". Blood. 115 (2). Bloodjournal.hematologylibrary.org: 168–186. doi: 10.1182/blood-2009-06-225565 . PMID   19846889. S2CID   22037567. Archived from the original on 2014-03-26. Retrieved 2014-01-16.
  18. ↑ "Clinical guidelines for testing for heritable thrombophilia" (PDF). 2010. Archived from the original (PDF) on 2014-01-16. Retrieved 2014-01-15.
  19. ↑ "Guideline for investigation and management of adults and children presenting with a thrombocytosis" (PDF). BCSH. 2010. Archived from the original (PDF) on 2013-01-16. Retrieved 2014-01-16.
  20. ↑ Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Stahel PF, Vincent JL, Spahn DR (2013-08-12). "Management of bleeding following major trauma: an updated European guideline". Crit Care. 14 (2): R52. doi: 10.1186/cc8943 . PMC   2887168 . PMID   20370902.
  21. ↑ "Venous thromboembolism – reducing the risk". Guidance.nice.org.uk. 2013-11-07. Archived from the original on 2014-01-16. Retrieved 2014-01-16.
  22. ↑ "VTE prevention". Guidance.nice.org.uk. 2013-04-15. Archived from the original on 2014-01-16. Retrieved 2014-01-16.
  23. ↑ "Lifeblood – Our History". Thrombosis-charity.org.uk. Archived from the original on 2008-06-18. Retrieved 2012-07-18.
  24. ↑ "World Thrombosis Day website". www.worldthrombosisday.org/. Archived from the original on 2022-10-20. Retrieved 2022-10-20.
  25. ↑ "King's doctor wins health innovator award – King's College Hospital NHS Foundation Trust". Kch.nhs.uk. 2010-01-27. Archived from the original on 2014-01-16. Retrieved 2012-07-18.
  26. ↑ "Meet the winners! — BMJ Group Awards". Groupawards.bmj.com. Retrieved 2012-07-18.[ permanent dead link ]
  27. ↑ "CRASH-2 – Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage". Crash2.lshtm.ac.uk. Archived from the original on 2011-10-05. Retrieved 2012-07-18.
  28. ↑ "News detail – King's Health Partners". Kingshealthpartners.org. 2011-05-20. Retrieved 2014-01-16.
  29. ↑ "No. 62666". The London Gazette (Supplement). 8 June 2019. p. B12.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.